Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Expanding diagnostics footprint in East India
Gilman will be responsible for all business development and portfolio strategy efforts globally.
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Subscribe To Our Newsletter & Stay Updated
